Publications

Preclinical

Categories
Preclinical
November 8, 2025
SITC
TriTCE Co-stim: A differentiated T cell engager platform with conditional cis CD28 co-stimulation and transferability to diverse targeting strategies
Verstrate et al.
Preclinical
November 7, 2025
SITC
High-throughput quantitative characterization of cytotoxic antibody-drug conjugates using spheroid models reveals important considerations in potential molecular mechanisms of ADC resistance
Church et al.
Preclinical
November 7, 2025
Design of a Next Generation Tumor Targeted Masked IL-12Fc for Enhanced Tolerability and Localized Anti-Tumor Activity
Escalante et al.
Preclinical
November 5, 2025
World ADC San Diego
ZW327 – A Topoisomerase-1 inhibitor ADC Designed to Target Ly6E-Expressing Tumors
Stuart Barnscher
Preclinical, ZW1528
September 30, 2025
ERS
ZW1528, a Bispecific Antibody Targeting IL-4Rα and IL-33, Potently Inhibits Key Mediators of Airway Inflammation
Hardman et al.
Preclinical, ZW1528
September 10, 2025 - September 10, 2025
World Bispecific Summit
ZW1528: A Dual-Targeting Bispecific Antibody to Broadly Suppress Airway Inflammation by Inhibiting IL-4Ra and IL-33 Pathways
Alexey Berezhnoy, PhD
Preclinical
August 11, 2025
Immuno-Oncology Summit
Engineering TrispecificT Cell Engager Leveraging Conditional CD28 Co-Stimulation to Treat Solid Tumors
Genevieve Desjardins, PhD
Preclinical
June 26, 2025
T cell Engager Summit
ZW209: A DLL3 Targeted Trispecific T Cell Engager with Conditional and Obligate cis CD28 Co-stimulation to Improve Responses in DLL3-Expressing Tumors
Nina Weisser, PhD
Preclinical, ZW1528
May 19, 2025
ATS
ZW1528, a Bispecific Antibody Targeting IL-4Rα and IL-33, Potently Inhibits Key Mediators of Airway Inflammation
Poffenberger et al.
Preclinical
April 30, 2025
AACR
ZW209, a DLL3 targeted trispecific T cell engager with integrated CD28 co-stimulation, demonstrates safety and potent preclinical efficacy in models of small cell lung cancer
Lau et al.
Preclinical
April 29, 2025
AACR
In vitro assays for prediction of ADC hematological toxicity: contribution of antibody, linker, and payload
Colombo et al.
Preclinical
April 28, 2025
AACR
ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload
Urosev et al.